Sesen Bio Investor Relations Material
Latest events
Investor Update
Sesen Bio
Q4 2023
1 Apr, 2024
Q4 2022
28 Feb, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sesen Bio Inc
Access all reports
Sesen Bio is developing fusion protein therapeutics for the treatment of patients with cancer based on a proprietary platform technology. This technology utilizes proprietary ligand design, a data-driven computational approach to molecular modeling, and molecular engineering to develop a library of novel fusion protein therapeutics. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SESN
Country
🇺🇸 United States